Evidence map›Paper›PMID 40856729›Full record

ReviewWorld journal of urology2025

Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

Benoit Peyronnet, Benjamin M Brucker, Cosimo De Nunzio, Christian Gratzke, John Heesakkers, Martin C Michel, Maurizio Serati, David Staskin, Christopher Chapple

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Benoit PeyronnetDepartment of Urology, Service dUrologie, Hopital Pontchaillou, University Hospital of Rennes, 2 Rue Henri Le Guilloux, 35000, Rennes, France. peyronnetbenoit@hotmail.fr.
Benjamin M BruckerDepartment of Urology and Obstetrics & Gynaecology, NYU Langone Health, New York, NY, USA.
Cosimo De NunzioDepartment of Urology, Ospedale Sant'Andrea, Sapienza University of Rome, Rome, Italy.
Christian GratzkeDepartment of Urology, Faculty of Medicine, University Freiburg, Freiburg Im Breisgau, Baden-Württemberg, Germany.
John HeesakkersDepartment of Urology, Maastricht UMC+, Maastricht, Netherlands.
Martin C MichelDepartment of Pharmacology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.ORCID http://orcid.org/0000-0003-4161-8467
Maurizio SeratiDepartment of Obstetrics and Gynecology, Urogynecology Unit, University of Insubria, Varese, Italy.
David StaskinTufts University School of Medicine, Boston, MA, USA.
Christopher ChappleSheffield Teaching Hospitals and The University of Sheffield, South Yorkshire, Sheffield, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOveractive bladder (OAB) is a prevalent and potentially debilitating syndrome that significantly impairs quality of life. Mirabegron and vibegron are β

methodsA comprehensive search of the PubMed database was conducted in December 2024 using the keyword "vibegron". This search yielded 123 entries, which were subsequently screened by title for relevance to the objectives of this narrative review. All relevant articles identified through this process were included.

resultsPivotal phase III trials have demonstrated significant reductions in urgency, urinary frequency and urgency urinary incontinence with vibegron, with rapid onset of action and a more favourable tolerability profile than antimuscarinics. The benefits of vibegron were consistent across diverse patient populations, including older adults and those with concomitant benign prostatic hyperplasia. Real-world data further suggest that vibegron is associated with improved adherence and persistence compared with other OAB therapies. Additionally, cardiovascular safety studies confirm that vibegron has no clinically significant effects on blood pressure or heart rate. While comparative trials with mirabegron indicate similar efficacy, vibegron's higher β

conclusionVibegron represents an important advance in the pharmacologic management of OAB, providing a well-tolerated and effective alternative to existing therapies.

Indexed as

Adrenergic beta-3 Receptor AgonistsPatient Reported Outcome MeasuresPyrrolidinesUrinary Bladder, OveractiveHumansPyrimidinonesTreatment OutcomeAdrenergic beta-3 Receptor AgonistsN-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamidePyrimidinonesPyrrolidinesOveractive bladderPharmacokineticsTreatment adherence and complianceVibegronβ3-adrenergic receptor agonistsβ3-adrenoceptor agonists

Identifiers

PMID40856729
PMCPMC12380879

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.